Resolving sepsis-induced immunoparalysis via trained immunity by targeting interleukin-4 to myeloid cells
David P Schrijver,Rutger J Röring,Jeroen Deckers,Anne de Dreu,Yohana C Toner,Geoffrey Prevot,Bram Priem,Jazz Munitz,Eveline G Nugraha,Yuri van Elsas,Anthony Azzun,Tom Anbergen,Laszlo A Groh,Anouk M D Becker,Carlos Pérez-Medina,Roderick S Oosterwijk,Boris Novakovic,Simone J C F M Moorlag,Aron Jansen,Peter Pickkers,Matthijs Kox,Thijs J Beldman,Ewelina Kluza,Mandy M T van Leent,Abraham J P Teunissen,Roy van der Meel,Zahi A Fayad,Leo A B Joosten,Edward A Fisher,Maarten Merkx,Mihai G Netea,Willem J M Mulder
DOI: https://doi.org/10.1038/s41551-023-01050-0
Abstract:Immunoparalysis is a compensatory and persistent anti-inflammatory response to trauma, sepsis or another serious insult, which increases the risk of opportunistic infections, morbidity and mortality. Here, we show that in cultured primary human monocytes, interleukin-4 (IL4) inhibits acute inflammation, while simultaneously inducing a long-lasting innate immune memory named trained immunity. To take advantage of this paradoxical IL4 feature in vivo, we developed a fusion protein of apolipoprotein A1 (apoA1) and IL4, which integrates into a lipid nanoparticle. In mice and non-human primates, an intravenously injected apoA1-IL4-embedding nanoparticle targets myeloid-cell-rich haematopoietic organs, in particular, the spleen and bone marrow. We subsequently demonstrate that IL4 nanotherapy resolved immunoparalysis in mice with lipopolysaccharide-induced hyperinflammation, as well as in ex vivo human sepsis models and in experimental endotoxemia. Our findings support the translational development of nanoparticle formulations of apoA1-IL4 for the treatment of patients with sepsis at risk of immunoparalysis-induced complications.